Naoya Hattori, Paul Sherwin, Gill Farrar. Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan. Journal of Alzheimer's disease reports. 2020. 4. 1. 165-174
Magota K, Shiga T, Asano Y, Shinyama D, Ye J, Perkins AE, Maniawski PJ, Toyonaga T, Kobayashi K, Hirata K, et al. Scatter correction with combined single-scatter simulation and Monte Carlo simulation scaling improved the visual artifacts and quantification in 3D brain PET/CT imaging with 15O-gas inhalation. J Nucl Med. 2017
Takuya Toyonaga, Shigeru Yamaguchi, Kenji Hirata, Kentaro Kobayashi, Osamu Manabe, Shiro Watanabe, Shunsuke Terasaka, Hiroyuki Kobayashi, Naoya Hattori, Tohru Shiga, et al. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European journal of nuclear medicine and molecular imaging. 2017. 44. 4. 611-619
Shiro Watanabe, Osamu Manabe, Kenji Hirata, Noriko Oyama-Manabe, Naoya Hattori, Yasuka Kikuchi, Kentaro Kobayashi, Takuya Toyonaga, Nagara Tamaki. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD). BMC cancer. 2016. 16. 635-635
Naoya Hattori, Shin Yamamoto, Seigo Nakano, Niki Udo, Kunihiro Nakada, Shogo Ohno, Mikako Ogawa, Hiroki Sugie. Basic clinical characteristics of dementia with Lewy bodies with vs. without concomitant beta-amyloid pathology. JOURNAL OF NUCLEAR MEDICINE. 2020. 61
Naoya Hattori, Shogo Ono, Niki Udo, Shin Yamamoto, Mikako Ogawa, Hiroki Sugie. Clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral A beta pathology in patients with various cognitive disorders. JOURNAL OF NUCLEAR MEDICINE. 2018. 59